ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,949.91
1.83%
Dow Jones
43,221.55
1.65%
US Dollar vs MXN
20.58395
0.61%
Brent Oil
81.125
-0.68%
Bitcoin
99,148.82
-1.36%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) Noticias

SNDX

Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SNDX
FechaHoraFuenteTítuloSímboloCompañía
15/01/202516:34PR Newswire (US)Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial SizesNASDAQ:SNDXSyndax Pharmaceuticals Inc
13/01/202506:00PR Newswire (US)Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
07/01/202520:20PR Newswire (US)Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:SNDXSyndax Pharmaceuticals Inc
07/01/202506:00PR Newswire (US)Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
03/01/202515:05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
20/12/202416:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/12/202406:30PR Newswire (US)Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination TrialNASDAQ:SNDXSyndax Pharmaceuticals Inc
07/12/202417:15PR Newswire (US)Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
06/12/202415:28Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SNDXSyndax Pharmaceuticals Inc
27/11/202406:00PR Newswire (US)Syndax Announces Participation at the Citi 2024 Global Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
15/11/202416:29PR Newswire (US)Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A TranslocationNASDAQ:SNDXSyndax Pharmaceuticals Inc
12/11/202406:00PR Newswire (US)Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of RevumenibNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202415:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202415:01PR Newswire (US)Syndax Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202408:01PR Newswire (US)Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202408:00PR Newswire (US)Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202408:00PR Newswire (US)Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
04/11/202415:01PR Newswire (US)Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™NASDAQ:SNDXSyndax Pharmaceuticals Inc
01/11/202406:00PR Newswire (US)Syndax Announces Participation in November Investor ConferencesNASDAQ:SNDXSyndax Pharmaceuticals Inc
29/10/202406:00PR Newswire (US)Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
18/09/202416:15PR Newswire (US)Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host DiseaseNASDAQ:SNDXSyndax Pharmaceuticals Inc
15/08/202415:15Business WireIncyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)NASDAQ:SNDXSyndax Pharmaceuticals Inc
15/08/202405:26Business WireIncyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)NASDAQ:SNDXSyndax Pharmaceuticals Inc
14/08/202416:34Business WireIncyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)NASDAQ:SNDXSyndax Pharmaceuticals Inc
12/08/202406:00PR Newswire (US)Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
01/08/202415:05PR Newswire (US)Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
29/07/202406:01PR Newswire (US)Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
25/07/202406:00PR Newswire (US)Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
17/06/202408:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
14/06/202406:00PR Newswire (US)Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 CongressNASDAQ:SNDXSyndax Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SNDX

Su Consulta Reciente

COIN
XRPUSD
Ripple
USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
XLF
Financial Select Sector
CCOM
SILVER
SILVER
AMEX
XLE
Energy Select Sector SPDR
NYSE
NKE
Nike
NYSE
MCD
McDonalds
FX
EURMXN
Euro vs MXN
COIN
SOLUSD
Solana
USOTC
ADDYY
Adidas (QX)
COIN
ETHUSD
Ethereum
NYSE
MRK
Merck
NYSE
KO
Coca Cola
USOTC
BASFY
BASF (QX)
USOTC
BNPQY
BNP Paribas (QX)
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados